Th17-Inducing Vaccines for the Treatment of Ovarian Cancer

Presented By: Keith Knutson, PhD

Speaker Biography: Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of Professor of Immunology, Mayo Clinic College of Medicine and Science. Dr. Knutson is also Director of the Mayo Clinic Cancer Center's Cancer Immunology and Immunotherapy Program. Dr. Knutson received his B.S. in Microbiology at the University of Washington. He earned his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed two postdoctoral fellowships in immunology, one at the University of British Columbia and the other at the University of Washington.

Webinar: Th17-Inducing Vaccines for the Treatment of Ovarian Cancer

Webinar Abstract: Ovarian cancer is a deadly disease which is usually diagnosed in advanced stages. Our goal is to develop vaccines to prevent relapse. Natural Th17 T cells protect against recurrence following conventional treatment. Thus, we developed a Th17 inducing vaccine targeting the folate receptor alpha and immunized patients following first line therapy. Vaccination resulted in prolonged relapse free survival and the development of immunity was associated with efficacy. Findings from the clinical trial as well as early insights into mechanisms of action will be discussed along with a new phase II clinical trial evaluating efficacy in a randomized controlled setting.

Earn PACE Credits:

LabRoots on Social:
SnapChat: labroots_inc